Botulinum toxin type A for the treatment of localized recalcitrant chronic pruritus

Boozalis, Emily; Sheu, Mary; Selph, Jacqueline; Kwatra, Shawn G.

doi:10.1016/j.jaad.2017.08.001

Cited by 13 publications

(15 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 204 , 205 ]. Botulinum toxin A may also alleviate itch in various disorders, including notalgia paresthetica, keloid, multiple sclerosis, brachioradial pruritus, and Fox–Fordyce disease [ 206 , 207 , 208 , 209 , 210 , 211 ].…”

Section: Therapeutic Targets For Pain and Itchmentioning

confidence: 99%

Druggable Targets and Compounds with Both Antinociceptive and Antipruritic Effects

et al. 2022

View full text Add to dashboard Cite

Pain and itch are both important manifestations of various disorders, such as herpes zoster, atopic dermatitis, and psoriasis. Growing evidence suggests that both sensations have shared mediators, overlapping neural circuitry, and similarities in sensitization processes. In fact, pain and itch coexist in some disorders. Determining pharmaceutical agents and targets for treating pain and itch concurrently is of scientific and clinical relevance. Here we review the neurobiology of pain and itch and discuss the pharmaceutical targets as well as novel compounds effective for the concurrent treatment of these sensations.

show abstract

Section: Therapeutic Targets For Pain and Itchmentioning

confidence: 99%

Druggable Targets and Compounds with Both Antinociceptive and Antipruritic Effects

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Neuropathic itch treatments being actively explored include injections of botulinum toxin and topical applications of ketamine mixtures or strontium. Botulinum toxin has been shown to improve, although with mixed results, neuropathic itch in brachioradial pruritus, notalgia paresthetica, and keloids [ 91 , 92 , 93 , 94 ]. Topical application of ketamine, mixed with amitryptyline and/or lidocaine, provided immediate relief for neuropathic itch patients [ 95 ].…”

Section: Future Therapeutic Directions For Neuropathic Itchmentioning

confidence: 99%

Neuropathic Itch

Meixiong

Dong

Weng

2020

Cells

View full text Add to dashboard Cite

Neurologic insults as varied as inflammation, stroke, and fibromyalgia elicit neuropathic pain and itch. Noxious sensation results when aberrantly increased afferent signaling reaches percept-forming cortical neurons and can occur due to increased sensory signaling, decreased inhibitory signaling, or a combination of both processes. To treat these symptoms, detailed knowledge of sensory transmission, from innervated end organ to cortex, is required. Molecular, genetic, and behavioral dissection of itch in animals and patients has improved understanding of the receptors, cells, and circuits involved. In this review, we will discuss neuropathic itch with a focus on the itch-specific circuit.

show abstract

“…Based on anecdotal reports in humans, the potential utility of various complementary treatment modalities remains to be elucidated more clearly in the future, e.g. regarding the 755 nm alexandrite laser, botulinum toxin, acupuncture, transcranial magnetic stimulation, extracorporeal shockwave therapy, massage with violet oil, positive verbal suggestions or music therapy [223][224][225][226][227][228][229][230][231].…”

Section: Miscellaneous Modalitiesmentioning

confidence: 99%

Emerging Therapeutic Options for Chronic Pruritus

2020

View full text Add to dashboard Cite

Chronic pruritus, defined as an unpleasant sensation resulting in a need to scratch that lasts more than 6 weeks, is a prevalent and bothersome symptom associated with both cutaneous and systemic conditions. Due to complex pathogenesis and profuse contributing factors, chronic pruritus therapy remains challenging. Regardless of the well-established antipruritic properties of classic pharmacotherapy (topical therapy, phototherapy and systemic therapy), these methods often provide insufficient relief for affected individuals. Owing to the growing interest in the field of pruritic research, further experimental and clinical data have emerged, continuously supporting the possibility of instigating novel therapeutic measures. This review covers the most relevant current modalities remaining under investigation that possess promising perspectives of approval in the near future, especially opioidergic drugs (mu-opioid antagonists and kappa-opioid agonists), neurokinin-1 receptor antagonists, biologic drugs, Janus kinase inhibitors, ileal bile acid transporter inhibitors, aryl hydrocarbon receptor agonists and histamine H 4 receptor antagonists.

show abstract

Botulinum toxin type A for the treatment of localized recalcitrant chronic pruritus

Cited by 13 publications

References 2 publications

Druggable Targets and Compounds with Both Antinociceptive and Antipruritic Effects

Druggable Targets and Compounds with Both Antinociceptive and Antipruritic Effects

Neuropathic Itch

Emerging Therapeutic Options for Chronic Pruritus

Contact Info

Product

Resources

About